Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study

• Published in: BMC genetics Vol. 15; no. 1; p. 28
• Main Authors: Kvehaugen, Anne Stine, Melien, Øyvind, Holmen, Oddgeir L, Laivuori, Hannele, Dechend, Ralf, Staff, Anne Cathrine
• Format: Journal Article
• Language: English
• Published: England BioMed Central 05.03.2014
• Subjects: Adult; Case-Control Studies; Deoxyribonucleic acid; Diabetes; DNA; Epidemiology; Exercise; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genetic testing; Genotype; Genotype & phenotype; Health risk assessment; Hospitals; Humans; Hypertension; Hypertension - epidemiology; Hypertension - genetics; Norway; Polymorphism, Single Nucleotide; Population; Pre-Eclampsia - epidemiology; Pre-Eclampsia - genetics; Preeclampsia; Pregnancy; Prevalence; Proteins; Public health; RGS Proteins - genetics; Risk Factors; Studies; Technological change; Womens health; Norway
• ISSN: 1471-2350; 1471-2156; 1471-2350; 1471-2156
• DOI: 10.1186/1471-2350-15-28

Preeclampsia is associated with an increased risk of hypertension later in life. The regulator of G protein signaling 2 negatively regulates several vasoconstrictors. We recently demonstrated an association between preeclampsia and the CG or GG genotype of the C1114G polymorphism (rs4606) of the regulator of G protein signaling 2 gene. Here, we examined the polymorphism with respect to the development of hypertension after pregnancy. We genotyped 934 women on average 15.1 years after preeclampsia and 2011 age matched women with previous normotensive pregnancy. All women in this study were retrospectively recruited from the Nord-Trøndelag Health Study (HUNT2). Information from HUNT2 was linked to the Medical Birth Registry of Norway to identify women with a history of preeclampsia and women without a history of preeclampsia. No significant association was found between hypertension (blood pressure ≥140/90 mmHg and/or taking antihypertensive drugs) and the polymorphism in crude analysis (OR (95% CI): CG genotype: 1.07 (0.90-1.27); GG genotype: 1.23 (0.90-1.67)). However, in a minimally adjusted model (age and BMI adjusted), a significant association between the GG genotype and hypertension was found (OR (95% CI): 1.49 (1.05-2.11)). This association remained significant also after adjustment for a history of preeclampsia (OR (95% CI): 1.46 (1.02-2.09)), but not in a model adjusted for multiple other variables (OR (95% CI): 1.26 (0.82-1.94)). In multivariate, but not in crude, analysis, the GG genotype of rs4606 (OR (95% CI): 1.93 (1.05-3.53)) was significantly and independently associated with severe hypertension later in life, defined as systolic blood pressure ≥160 mmHg (stage 2 hypertension) and/or taking antihypertensive drugs. A significant association was also found for the merged CG and GG genotypes (OR (95% CI): 1.43 (1.02-2.00)). Moreover, an interaction with physical activity was found. A history of preeclampsia was a significant and independent predictor of either definition of hypertension, both in crude and adjusted analyses. Women carrying the rs4606 CG or GG genotype are at elevated risk for developing hypertension after delivery. Physical activity may interact with the association. Preeclampsia remains an independent risk factor for subsequent hypertension after adjusting for this polymorphism and classical CVD risk factors.